Literature DB >> 33848431

Simulating Outcomes of Cataract Surgery: Important Advances in Ophthalmology.

Susana Marcos1, Eduardo Martinez-Enriquez1, Maria Vinas1, Alberto de Castro1, Carlos Dorronsoro1,2, Seung Pil Bang3, Geunyoung Yoon3, Pablo Artal4.   

Abstract

As the human eye ages, the crystalline lens stiffens (presbyopia) and opacifies (cataract), requiring its replacement with an artificial lens [intraocular lens (IOL)]. Cataract surgery is the most frequently performed surgical procedure in the world. The increase in IOL designs has not been paralleled in practice by a sophistication in IOL selection methods, which rely on limited anatomical measurements of the eye and the surgeon's interpretation of the patient's needs and expectations. We propose that the future of IOL selection will be guided by 3D quantitative imaging of the crystalline lens to map lens opacities, anticipate IOL position, and develop fully customized eye models for ray-tracing-based IOL selection. Conversely, visual simulators (in which IOL designs are programmed in active elements) allow patients to experience prospective vision before surgery and to make more informed decisions about which IOL to choose. Quantitative imaging and optical and visual simulations of postsurgery outcomes will allow optimal treatments to be selected for a patient undergoing modern cataract surgery.

Entities:  

Keywords:  adaptive optics; anterior segment imaging; cataract surgery; intraocular lens; optical coherence tomography; visual simulation

Mesh:

Year:  2021        PMID: 33848431     DOI: 10.1146/annurev-bioeng-082420-035827

Source DB:  PubMed          Journal:  Annu Rev Biomed Eng        ISSN: 1523-9829            Impact factor:   9.590


  1 in total

1.  Intraocular scatter compensation with spatial light amplitude modulation for improved vision in simulated cataractous eyes.

Authors:  Spozmai Panezai; Alfonso Jiménez-Villar; Alba M Paniagua Diaz; Augusto Arias; Grzegorz Gondek; Silvestre Manzanera; Pablo Artal; Ireneusz Grulkowski
Journal:  Biomed Opt Express       Date:  2022-03-16       Impact factor: 3.562

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.